Breaking News

Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

Exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ajinomoto Bio-Pharma Services, a biopharmaceutical CDMO, and Bright Peak Therapeutics Inc., a biotechnology company developing next gen immunotherapies for cancer and autoimmune disease, have entered a research collaboration and exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.   Bright Peak uses a novel ligation technology to chemically synthesize therapeutic cytokines by ligating toget...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters